Insider Trading & Ownership of RA CAPITAL MANAGEMENT, L.P.

Location
Boston, MA
Summary
The estimated value of insider holdings of RA CAPITAL MANAGEMENT, L.P. is at least $1,297,787,946 dollars as of 02 Mar 2026. RA CAPITAL MANAGEMENT, L.P. is the Former 10% Owner of iTeos Therapeutics, Inc. and owns shares of iTeos Therapeutics, Inc. stock worth about $137.05M. RA CAPITAL MANAGEMENT, L.P. is the Director, 10%+ Owner of Cytek Biosciences, Inc. and owns shares of Cytek Biosciences, Inc. (CTKB) stock worth about $127.12M. RA CAPITAL MANAGEMENT, L.P. is the Director, 10%+ Owner of Wave Life Sciences Ltd. and owns shares of Wave Life Sciences Ltd. (WVE) stock worth about $121.73M. RA CAPITAL MANAGEMENT, L.P. is the Director, 10%+ Owner of Tyra Biosciences, Inc. and owns shares of Tyra Biosciences, Inc. (TYRA) stock worth about $116.94M. RA CAPITAL MANAGEMENT, L.P. is the Director, 10%+ Owner of Bicara Therapeutics Inc. and owns shares of Bicara Therapeutics Inc. (BCAX) stock worth about $108.85M. RA CAPITAL MANAGEMENT, L.P. is the Director, 10%+ Owner of Vor Biopharma Inc. and owns shares of Vor Biopharma Inc. (VOR) stock worth about $108.43M. RA CAPITAL MANAGEMENT, L.P. is the 10%+ Owner of Fulcrum Therapeutics, Inc. and owns shares of Fulcrum Therapeutics, Inc. (FULC) stock worth about $90.69M. RA CAPITAL MANAGEMENT, L.P. is the Director of Evommune, Inc. and owns shares of Evommune, Inc. (EVMN) stock worth about $75.56M. RA CAPITAL MANAGEMENT, L.P. is the 10%+ Owner of 4D Molecular Therapeutics, Inc. and owns shares of 4D Molecular Therapeutics, Inc. (FDMT) stock worth about $74.52M. RA CAPITAL MANAGEMENT, L.P. is the Director, 10%+ Owner of PepGen Inc. and owns shares of PepGen Inc. (PEPG) stock worth about $59.37M. RA CAPITAL MANAGEMENT, L.P. is the Director, 10%+ Owner of SpyGlass Pharma, Inc. and owns shares of SpyGlass Pharma, Inc. (SGP) stock worth about $57.18M. RA CAPITAL MANAGEMENT, L.P. is the 10%+ Owner of Kala Pharmaceuticals, Inc. and owns shares of KALA BIO, Inc. (KALA) stock worth about $47.45M. RA CAPITAL MANAGEMENT, L.P. is the Director, 10%+ Owner of 89bio, Inc. and owns shares of 89bio, Inc. stock worth about $36.81M. RA CAPITAL MANAGEMENT, L.P. is the Former 10% owner of Enliven Therapeutics, Inc. and owns shares of Enliven Therapeutics, Inc. (ELVN) stock worth about $32.12M. RA CAPITAL MANAGEMENT, L.P. is the Director, 10%+ Owner of Cidara Therapeutics, Inc. and owns shares of Cidara Therapeutics, Inc. stock worth about $19.19M. RA CAPITAL MANAGEMENT, L.P. is the 10%+ Owner of Solid Biosciences Inc. and owns shares of Solid Biosciences Inc. (SLDB) stock worth about $15M. RA CAPITAL MANAGEMENT, L.P. is the Director of Therapeutics Acquisition Corp. and owns shares of POINT Biopharma Global Inc. stock worth about $13.67M. RA CAPITAL MANAGEMENT, L.P. is the Director, 10%+ Owner of Climb Bio, Inc. and owns shares of Climb Bio, Inc. (CLYM) stock worth about $11.91M. RA CAPITAL MANAGEMENT, L.P. is the 10%+ Owner of RxSight, Inc. and owns shares of RxSight, Inc. (RXST) stock worth about $10.27M. RA CAPITAL MANAGEMENT, L.P. is the Director of Black Diamond Therapeutics, Inc. and owns shares of Black Diamond Therapeutics, Inc. (BDTX) stock worth about $8.77M. RA CAPITAL MANAGEMENT, L.P. is the Director, 10%+ Owner of Septerna, Inc. and owns shares of Septerna, Inc. (SEPN) stock worth about $8.61M. RA CAPITAL MANAGEMENT, L.P. is the Director, 10%+ Owner of Sionna Therapeutics, Inc. and owns shares of Sionna Therapeutics, Inc. (SION) stock worth about $6.28M. RA CAPITAL MANAGEMENT, L.P. is the Director, 10%+ Owner of Werewolf Therapeutics, Inc. and owns shares of Werewolf Therapeutics, Inc. (HOWL) stock worth about $6.11M. RA CAPITAL MANAGEMENT, L.P. is the 10%+ Owner of Aerovate Therapeutics, Inc. and owns shares of Jade Biosciences, Inc. (JBIO) stock worth about $3.44M. RA CAPITAL MANAGEMENT, L.P. is the 10%+ Owner of AN2 Therapeutics, Inc. and owns shares of AN2 Therapeutics, Inc. (ANTX) stock worth about $324.9K. RA CAPITAL MANAGEMENT, L.P. is the Director of Mineralys Therapeutics, Inc. and owns shares of Mineralys Therapeutics, Inc. (MLYS) stock worth about $212.5K. RA CAPITAL MANAGEMENT, L.P. is the Director, 10%+ Owner of Janux Therapeutics, Inc. and owns shares of Janux Therapeutics, Inc. (JANX) stock worth about $159.8K. RA CAPITAL MANAGEMENT, L.P. is the Director, 10%+ Owner of Acumen Pharmaceuticals, Inc. and owns shares of Acumen Pharmaceuticals, Inc. (ABOS) stock worth about $14.1K.
Signature
/s/ Peter Kolchinsky, Manager of RA Capital Management, L.P.
All Insider Reports
All Insider Reports

Notify me when RA CAPITAL MANAGEMENT, L.P. files a new Insider Trading report.

⭐ Subscribe ⭐

Ownership of RA CAPITAL MANAGEMENT, L.P.

Symbol Company Relationship Holdings Value Past Year Net Change Change % Report Period
ITOS iTeos Therapeutics, Inc. Former 10% Owner $137,049,292 10 May 2024
CTKB Cytek Biosciences, Inc. Director, 10%+ Owner $127,120,013 14 Mar 2022
WVE Wave Life Sciences Ltd. Director, 10%+ Owner $121,732,622 +$6,688 +0.01% 13 Nov 2025
TYRA Tyra Biosciences, Inc. Director, 10%+ Owner $116,935,617 +$15,320,006 +15% 12 Jun 2025
BCAX Bicara Therapeutics Inc. Director, 10%+ Owner $108,854,468 +$39,999,780 +58% 26 Feb 2026
VOR Vor Biopharma Inc. Director, 10%+ Owner $108,428,028 -$33,715,155 -24% 18 Dec 2025
FULC Fulcrum Therapeutics, Inc. 10%+ Owner $90,688,320 -$58,377,021 -39% 08 Dec 2025
EVMN Evommune, Inc. Director $75,562,968 17 Feb 2026
FDMT 4D Molecular Therapeutics, Inc. 10%+ Owner $74,517,236 09 Dec 2024
PEPG PepGen Inc. Director, 10%+ Owner $59,373,673 +$30,000,000 +102% 26 Sep 2025
SGP SpyGlass Pharma, Inc. Director, 10%+ Owner $57,181,689 09 Feb 2026
KALA Kala Pharmaceuticals, Inc. 10%+ Owner $47,446,992 26 May 2022
ETNB 89bio, Inc. Director, 10%+ Owner $36,809,857 30 Oct 2025
ELVN Enliven Therapeutics, Inc. Former 10% owner $32,123,508 23 Feb 2023
CDTX Cidara Therapeutics, Inc. Director, 10%+ Owner $19,188,424 +$99,999,988 07 Jan 2026
SLDB Solid Biosciences Inc. 10%+ Owner $14,996,280 19 Feb 2025
PNT Therapeutics Acquisition Corp. Director $13,674,059 29 Jun 2021
CLYM Climb Bio, Inc. Director, 10%+ Owner $11,912,001 +$779,626 +7% 05 Jan 2026
RXST RxSight, Inc. 10%+ Owner $10,265,312 03 Aug 2021
BDTX Black Diamond Therapeutics, Inc. Director $8,773,750 05 Jul 2023
SEPN Septerna, Inc. Director, 10%+ Owner $8,610,867 17 Jun 2025
SION Sionna Therapeutics, Inc. Director, 10%+ Owner $6,281,803 -$21,463,466 -77% 20 Nov 2025
HOWL Werewolf Therapeutics, Inc. Director, 10%+ Owner $6,112,732 +$487,188 +8.7% 12 May 2025
JBIO Aerovate Therapeutics, Inc. 10%+ Owner $3,437,148 28 Apr 2025
ANTX AN2 Therapeutics, Inc. 10%+ Owner $324,921 09 Aug 2024
MLYS Mineralys Therapeutics, Inc. Director $212,536 +$47,499,981 19 Feb 2026
JANX Janux Therapeutics, Inc. Director, 10%+ Owner $159,750 11 Jun 2025
ABOS Acumen Pharmaceuticals, Inc. Director, 10%+ Owner $14,080 04 Jun 2025
ICVX Icosavax, Inc. Director, 10%+ Owner $0 19 Feb 2024
ACRV Acrivon Therapeutics, Inc. Director, 10%+ Owner 13 Jun 2025
SPRY ARS Pharmaceuticals, Inc. Director, 10%+ Owner 25 Jun 2025
ARTV Artiva Biotherapeutics, Inc. Director, 10%+ Owner 24 Jun 2025
BOLD Boundless Bio, Inc. 10%+ Owner 02 Apr 2024
DICE DICE Therapeutics, Inc. Former 10% owners and Director 09 Aug 2023
FMTX Forma Therapeutics Holdings, Inc. Director, 10%+ Owner 14 Oct 2022
LENZ LENZ Therapeutics, Inc. Director, 10%+ Owner 11 Jun 2025
NKTX Nkarta, Inc. Director, 10%+ Owner 05 Jun 2025
STSA Satsuma Pharmaceuticals, Inc. Former 10% Owner 08 Jun 2023

Insider Transactions Reported by RA CAPITAL MANAGEMENT, L.P.:

Sym Company Class Transaction % Value $ * Price $ Shares Shares After Date Ownership
* An asterisk sign (*) next to the price indicates that the price is likely invalid.